Trial Profile
Anti-atherosclerotic effect of repaglinide or glimepiride in Japanese type 2 diabetic patients
Status:
Discontinued
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 06 Aug 2015
Price :
$35
*
At a glance
- Drugs Glimepiride (Primary) ; Repaglinide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 11 Aug 2014 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 13 Jul 2012 New trial record